title: Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.
abstract: OBJECTIVE
  This study was designed to assess the physicochemical stability of colloidal ferric carboxymaltose solution (Ferinject) when diluted and stored in polypropylene (PP) bottles and bags for infusion.
  
  
  METHODS
  Two batches of ferric carboxymaltose solution (Ferinject) were diluted (500 mg, 200 mg and 100 mg iron in 100 mL saline) in PP bottles or bags under aseptic conditions. The diluted solutions were stored at 30°C and 75%±5% relative humidity (rH) for 72 h, and samples were withdrawn aseptically at preparation and after 24 h, 48 h and 72 h. Multiple parameters were used to test stability-related measures (pH, total iron and iron (II) content, molecular weight range determination, microbial contamination and particles count ≥10 μm).
  
  
  RESULTS
  Overall, Ferinject diluted in 0.9% (w/v) NaCl solution and stored in PP bottles and bags was stable within the specifications for the complex and the acceptability limits set for all assays. In both containers, total iron content remained stable, within 10% of the theoretical iron content, and levels of iron (II) remained far below the threshold of acceptability. All preparations were free from sediments, particle numbers were acceptable and there was no microbial contamination. The molecular weight distribution and polydispersity index were also acceptable.
  
  
  CONCLUSIONS
  Under the tested experimental conditions, colloidal ferric carboxymaltose solution (Ferinject) diluted in saline in PP infusion bottles or bags demonstrated physical and chemical stability for up to 72 h at 30°C and 75% rH. Because of the lack of additional clinical data, when using ferric carboxymaltose, physicians/pharmacists should refer to the dilution and storing recommendations given in the product's summary of product characteristics.
authors.affiliation: Vifor (International) AG , St. Gallen , Switzerland.
authors.forename: Erik
authors.initials: E
authors.lastname: Philipp
authors.affiliation: Vifor (International) AG , St. Gallen , Switzerland.
authors.forename: Michaela
authors.initials: M
authors.lastname: Braitsch
authors.affiliation: Laboratorium Dr. G. Bichsel AG , Unterseen , Switzerland.
authors.forename: Tobias
authors.initials: T
authors.lastname: Bichsel
authors.affiliation: Vifor Pharma Ltd. , Glattbrugg , Switzerland.
authors.forename: Stefan
authors.initials: S
authors.lastname: Mühlebach
keywords: CLINICAL PHARMACY; STABILITY AND INCOMPATIBILITY
references.citation: Public Health Nutr. 2005 Apr;8(2):117-32
references.pmid: 15877905
references.citation: Ann N Y Acad Sci. 2014 Apr;1313:35-56
references.pmid: 24673240
references.citation: J Am Coll Cardiol. 2008 Jan 15;51(2):103-12
references.pmid: 18191732
references.citation: Am J Nephrol. 2007;27(6):565-71
references.pmid: 17804903
references.citation: Arzneimittelforschung. 2010;60(6a):399-412
references.pmid: 20648931
references.citation: AAPS J. 2014 Jan;16(1):11-4
references.pmid: 24065599
references.citation: Eur Heart J. 2013 Jan;34(1):30-8
references.pmid: 22297124
references.citation: Am J Clin Nutr. 2003 Jan;77(1):234-41
references.pmid: 12499347
references.citation: J Nutr. 2001 Feb;131(2S-2):568S-579S; discussion 580S
references.pmid: 11160590
references.citation: Nanomedicine (Lond). 2013 May;8(5):849-56
references.pmid: 23656268
references.citation: Pediatrics. 2003 Oct;112(4):846-54
references.pmid: 14523176
references.citation: Front Pharmacol. 2014 Jul 10;5:156
references.pmid: 25071575
references.citation: Eur Heart J. 2013 Mar;34(11):816-29
references.pmid: 23100285
references.citation: Am J Clin Nutr. 2004 Mar;79(3):437-43
references.pmid: 14985219
references.citation: Blood. 2014 Jan 30;123(5):615-24
references.pmid: 24297872
references.citation: Arzneimittelforschung. 1992 Dec;42(12 ):1439-52
references.pmid: 1288508
references.citation: Blood. 2010 Dec 2;116(23):4754-61
references.pmid: 20826717
references.citation: Public Health Nutr. 2006 Oct;9(7):904-20
references.pmid: 17010257
references.citation: J Nutr. 2001 Feb;131(2S-2):649S-666S; discussion 666S-668S
references.pmid: 11160596
references.citation: Br J Haematol. 2003 Aug;122(4):554-62
references.pmid: 12899710
references.citation: AAPS J. 2014 Jan;16(1):15-21
references.pmid: 24065600
references.citation: Curr Med Res Opin. 2013 Feb;29(2):141-7
references.pmid: 23252876
references.citation: Gastroenterology. 2011 Sep;141(3):846-853.e1-2
references.pmid: 21699794
references.citation: Drugs. 2009;69(6):739-56
references.pmid: 19405553
references.citation: N Engl J Med. 2009 Dec 17;361(25):2436-48
references.pmid: 19920054
references.citation: J Nutr. 2001 Feb;131(2S-2):676S-688S; discussion 688S-690S
references.pmid: 11160598
references.citation: Lancet. 1949 Apr 23;1(6556):686-9
references.pmid: 18118003
references.citation: Arzneimittelforschung. 2010;60(6a):345-53
references.pmid: 20648926